Cart
sales@molnova.com
Mopidamol
CAS No. 13665-88-8
Mopidamol( —— )
Catalog No. M34106 CAS No. 13665-88-8
Mopidamol (RA 233) is a phosphodiesterase inhibitor, a dipyridamole derivative, with anticancer activity that prevents retinal vascular defects in experimental diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 578 | Get Quote |
|
| 5MG | 845 | Get Quote |
|
| 10MG | 1169 | Get Quote |
|
| 25MG | 1684 | Get Quote |
|
| 50MG | 2006 | Get Quote |
|
| 100MG | 2520 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameMopidamol
-
NoteResearch use only, not for human use.
-
Brief DescriptionMopidamol (RA 233) is a phosphodiesterase inhibitor, a dipyridamole derivative, with anticancer activity that prevents retinal vascular defects in experimental diabetes.
-
DescriptionMopidamol (RA 233) is a phosphodiesterase inhibitor, a dipyridamole derivative, with anticancer activity that prevents retinal vascular defects in experimental diabetes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number13665-88-8
-
Formula Weight421.49
-
Molecular FormulaC19H31N7O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(CCO)(CCO)C1=NC=2C(=NC(N(CCO)CCO)=NC2C=N1)N3CCCCC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Pterine-6-carboxylic...
Pterine-6-carboxylic acid (6-Carboxypterin) is a photodegradation product of folic acid, which can be used as a photosensitive agent to study the molecular mechanism of UVA breaking DNA structure.
-
TAK-063
TAK-063 (Balipodect) is a highly potent, selective, orally active PDE10A inhibitor with IC50 of 0.3 nM.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
